CN110167944B - 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 - Google Patents

取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 Download PDF

Info

Publication number
CN110167944B
CN110167944B CN201780076412.5A CN201780076412A CN110167944B CN 110167944 B CN110167944 B CN 110167944B CN 201780076412 A CN201780076412 A CN 201780076412A CN 110167944 B CN110167944 B CN 110167944B
Authority
CN
China
Prior art keywords
ethyl
spiro
tetrahydropyran
oxo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780076412.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167944A (zh
Inventor
梁锡福
J·拉森
S·F·尼尔森
P·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combination Therapy Co
Original Assignee
Combination Therapy Co
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combination Therapy Co, Leo Pharma AS filed Critical Combination Therapy Co
Publication of CN110167944A publication Critical patent/CN110167944A/zh
Application granted granted Critical
Publication of CN110167944B publication Critical patent/CN110167944B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780076412.5A 2016-12-12 2017-12-12 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 Expired - Fee Related CN110167944B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16203335 2016-12-12
EP16203335.1 2016-12-12
PCT/EP2017/082424 WO2018108910A1 (en) 2016-12-12 2017-12-12 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
CN110167944A CN110167944A (zh) 2019-08-23
CN110167944B true CN110167944B (zh) 2024-08-23

Family

ID=57542834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780076412.5A Expired - Fee Related CN110167944B (zh) 2016-12-12 2017-12-12 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途

Country Status (7)

Country Link
US (2) US11065257B2 (https=)
EP (1) EP3551632B1 (https=)
JP (1) JP7008073B2 (https=)
CN (1) CN110167944B (https=)
ES (1) ES2981006T3 (https=)
RU (1) RU2768746C2 (https=)
WO (1) WO2018108910A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3642210T3 (da) 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803299B1 (fr) * 2000-01-05 2004-09-17 Warner Lambert Co NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
WO2004098520A2 (en) 2003-05-01 2004-11-18 Irm Llc Compounds and compositions as protein kinase inhibitors
TW200745106A (en) 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
ES2372320T3 (es) * 2006-11-15 2012-01-18 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteínas quinasas.
CA2676933C (en) * 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
GB0704652D0 (en) 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2018108231A1 (en) 2016-12-12 2018-06-21 Leo Pharma A/S Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors
JP6850886B2 (ja) 2016-12-12 2021-03-31 レオ ファーマ アクティーゼルスカブ 置換ピラゾロアゼピン−４−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用

Also Published As

Publication number Publication date
WO2018108910A1 (en) 2018-06-21
RU2019121694A3 (https=) 2021-01-21
US20200323869A1 (en) 2020-10-15
JP2020511410A (ja) 2020-04-16
RU2768746C2 (ru) 2022-03-24
EP3551632C0 (en) 2024-06-12
EP3551632A1 (en) 2019-10-16
JP7008073B2 (ja) 2022-01-25
EP3551632B1 (en) 2024-06-12
RU2019121694A (ru) 2021-01-12
US11065257B2 (en) 2021-07-20
US20220362259A1 (en) 2022-11-17
ES2981006T3 (es) 2024-10-04
CN110167944A (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
CN116648452B (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
EP3740478B1 (en) Fused imidazole derivatives as il-17 modulators
EP2675812B1 (en) Chroman - spirocyclic piperidine amides as modulators of ion channels
EP2404922B1 (en) Quinoxaline compounds
US8497264B2 (en) Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
JP2018108997A (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
KR20130098269A (ko) 테트라히드로카르볼린 유도체
EP2209790B1 (en) Equilibrative nucleoside transporter ent1 inhibitors
CN111108109A (zh) 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
WO2020241853A1 (ja) ベンゾトリアゾール誘導体
CN111712503A (zh) 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
CN110167944B (zh) 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途
CN110088108B (zh) 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途
CN111727191A (zh) 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
CN110099905B (zh) 取代的吡唑并氮杂䓬-8-酮类及其作为磷酸二酯酶抑制剂的用途
CN106565674B (zh) 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
HK40103822A (en) Preparation and application method of heterocyclic compound as kras inhibitor
AU2023283530A1 (en) Pyridazin-3-carboxamide compound as tyk2 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210702

Address after: Dane Heller Rupp

Applicant after: Combination therapy Co.

Address before: Denmark and Rupp

Applicant before: LEO PHARMA A/S

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240823

CF01 Termination of patent right due to non-payment of annual fee